A Complete Guide to Wilson’s Disease

Wilson’s disease is an inherited condition in which the body cannot get rid of extra copper, so copper slowly builds up in the liver, the brain and the eyes [1,2].

This page provides general information. It does not replace advice from a doctor or another qualified healthcare professional.

Key facts

Copper from food is needed in small amounts. In Wilson’s disease the liver cannot pass extra copper into bile for removal, so it builds up and damages tissue [2,3].
It is caused by changes in a gene called ATP7B and is passed on in an autosomal recessive pattern, meaning a person inherits one changed copy from each parent [1,2].
The commonly quoted figure is about 1 in 30,000 people, though genetic studies suggest the true number may be higher [1,2,3].
Symptoms usually start between the ages of 6 and 45 and can involve the liver, movement, mood and thinking, in almost any combination [1,2].
Diagnosis is often delayed. In one large study the average time from first symptoms to diagnosis was 22.5 months [6].
Wilson’s disease is treatable. Without treatment it is progressive and eventually fatal, while with lifelong treatment started early the long-term outlook is very good [4,7].

What is Wilson’s disease?

Copper is a metal found in ordinary foods. The body needs a small amount of it, and the liver removes what is left over by passing it into bile, the fluid that drains from the liver into the gut [3].

In Wilson’s disease that removal step does not work. Copper builds up in the liver, then spills into the bloodstream and settles elsewhere, above all in the brain and also in the eyes, kidneys and heart [1,4]. Copper in these amounts is toxic, damaging liver cells and, later, the parts of the brain that control movement and mood [1,4]. Other names for the condition are hepatolenticular degeneration and copper storage disease [2].

It is easily confused with other conditions, and the treatments differ completely. Hemochromatosis is a build-up of iron, not copper. Early liver symptoms can look like viral hepatitis, and early movement symptoms like essential tremor or early-onset Parkinson’s disease [4].

How common is it?

The figure quoted most often is about 1 in 30,000 people, with roughly 1 in 90 carrying a single changed copy of the gene without being affected [1]. Orphanet gives a birth prevalence range of 1 in 30,000 to 1 in 110,000 worldwide, higher in some isolated populations [4].

There is an unresolved question underneath those numbers. Studies that look directly at people’s genes keep finding the gene changes more often than the clinical figures predict. A genetic study in the United Kingdom found changes linked to Wilson’s disease in about 1 in 7,000 people [3]. An analysis of a large genomic database calculated around 1 in 2,400, then roughly 1 in 20,000 after removing variants judged unlikely to cause illness [5].

Two explanations are usually given, and both may be partly true. Some people with the condition are never diagnosed. Others carry two changed copies of the gene and never become ill [3,5]. Registry figures count only people who have been diagnosed, so the real number is uncertain and is probably higher than 1 in 30,000.

What causes it?

Genes are instructions inside our cells. Wilson’s disease is caused by changes, also called variants, in a gene named ATP7B on chromosome 13. That gene carries instructions for a protein that moves copper out of liver cells, and when the protein does not work, copper cannot be cleared [2,4].

Wilson’s disease is inherited in an autosomal recessive pattern. A person needs two changed copies of the gene, one from each parent. Parents who each carry one changed copy are called carriers and are usually completely well [2]. Where both parents are carriers, each pregnancy carries a 25 percent chance that the child will have the condition [1].

Family screening picks up around 20 percent of all cases, and guidelines recommend testing all first-degree relatives, meaning parents, brothers and sisters, and children [1,4]. No clear link has been found between which gene change a person has and how severe their illness becomes, so two relatives with the same variants can be affected very differently [1].

What are the symptoms?

Symptoms usually begin between the ages of 6 and 45, most often in the teenage years, though the condition has been found in children as young as three and in adults over 70 [1,2]. About 40 percent of people first come to attention with liver problems, about 40 percent with movement problems and about 20 percent with changes in mood or behavior [1]. Children under 18 most often have liver disease alone [1].

Liver. Yellowing of the skin or eyes, tiredness, loss of appetite, tummy pain, swelling of the abdomen, or an abnormal liver blood test found by chance [1,2].
Movement and speech. Tremor, clumsiness, smaller and more cramped handwriting, stiffness, a changed walk, slurred speech or difficulty swallowing [1,4].
Mood and thinking. Depression is common, along with anxiety, irritability, personality change and difficulty concentrating [1,4].
Eyes. Copper can form a green-to-brown ring at the edge of the colored part of the eye, called a Kayser-Fleischer ring. It does not affect vision, fades with treatment, and is found in about 90 percent of people whose first symptoms affect movement [1,2].
Elsewhere. Sudden breakdown of red blood cells, kidney problems, joint pain and thinner bones [1,4].

When to seek urgent help. The liver can occasionally fail suddenly, and around 5 percent of people already have acute liver failure when first diagnosed [3]. Signs needing emergency care include rapidly deepening jaundice, confusion or unusual drowsiness, easy bruising or bleeding, and dark urine with sudden paleness [1,3]. This is treated as an emergency.

How is it diagnosed?

A family doctor usually starts the process. Care is then led by a hepatologist, a doctor specializing in the liver, often with a neurologist, a clinical geneticist and an eye specialist [1,4].

No single test settles it. Doctors put several results together [1,4]:

Serum ceruloplasmin, a blood test for the main copper-carrying protein, usually low. It is not reliable alone, being normal in up to 40 percent of people with liver findings [1].
Serum copper, usually low, and 24-hour urinary copper, usually raised and often collected on three separate days [1].
An eye examination with a slit lamp, a special microscope, to look for Kayser-Fleischer rings, and a brain MRI scan where there are movement or speech symptoms [1].
A liver biopsy, measuring the copper content of a small sample of liver, used when other results are unclear [1].
Genetic testing of ATP7B, which finds the responsible change in about 98 percent of people [1,4].

Results are combined in a scoring system agreed by international experts, called the Leipzig score [1].

Diagnosis is frequently late. In a Polish study of 268 adults, the average gap between first symptoms and diagnosis was 22.5 months, shortest for liver symptoms and longest for psychiatric symptoms at 65 months, and longer delay was linked to worsening neurological symptoms [6]. Early symptoms look like far more common conditions, so a rare disease is not considered first.

How is it treated?

Wilson’s disease is treatable, and this is the most important thing to understand about it. Treatment continues for life, including during pregnancy [1,4]. Left untreated, the condition gets steadily worse and is eventually fatal [4]. Started early and taken consistently, treatment gives a very good long-term outlook [4].

Chelating agents bind copper so it leaves the body in urine. Penicillamine has been used since the 1950s and is taken by mouth alongside vitamin B6. Serious side effects occur in up to 30 percent of people, so blood counts and urine are checked regularly. Trientine is the usual alternative, and a newer trientine formulation showed better tolerance in a trial, supporting its use as a first choice [1].

Zinc salts taken by mouth block copper from being absorbed in the gut. Zinc works best once copper stores have been brought down with a chelating agent, and the two are not taken together [1].

Diet. Foods very high in copper, including liver, chocolate, mushrooms, shellfish and nuts, are avoided, particularly early on. Alcohol is discouraged where liver blood tests are abnormal [1].

Liver transplantation corrects the underlying problem and is used where the liver fails suddenly or medicines do not work [1].

Blood tests, urine tests and a physical check are recommended at least twice a year [1]. Relatives found through screening who feel well are treated too, usually at a lower dose [1]. Availability and funding of medicines differ between countries.

Living with Wilson’s disease

Taking treatment consistently is the most important part of daily life. Stopping all treatment leads to the liver and nervous system deteriorating, and that deterioration often does not respond to restarting medicine [1].

Care works best through a center used to seeing the condition, which may involve a liver specialist, a neurologist, a dietitian, a speech and language therapist and a psychologist [1]. Carrying a note of the diagnosis and current medicines is sensible, since the condition is unfamiliar to many clinicians.

Most people with Wilson’s disease are fertile [1]. Treatment continues through pregnancy at the lowest effective dose, and breastfeeding while taking copper-lowering medicine is generally not recommended [1]. Depression can be part of the condition as well as a reaction to it, and either is worth raising with the care team.

Thinking about a clinical trial?

Clinical trials are research studies that test whether a treatment works and is safe. Wilson’s disease already has effective treatments, and research is now looking at newer medicines and at one-off gene therapies. Deciding whether to look into a study is a personal choice.

1. Understand what the study is asking

It is worth being clear on what a study actually involves:

what the researchers are trying to learn, and what treatment is being studied and compared against
how long the study lasts, which for Wilson’s disease can be several years
what visits and tests are involved and how often, including whether 24-hour urine collections, scans or a liver biopsy are required
whether travel to a study site is needed, and how far
the possible benefits, and the known and unknown risks
what happens when the study ends, including whether treatment continues

2. Consider possible medical suitability

Every trial has rules about who can take part. These are called eligibility criteria. Some describe who can join, and others describe who cannot. For a Wilson’s disease study, they might include a diagnosis confirmed by genetic testing, stable treatment with a chelating agent or zinc for a set period, an age range, how well the liver is working, whether a person has had a liver transplant, and how severe any movement or psychiatric symptoms are.

trialport’s medifit helps people consider information related to possible medical suitability. It does not diagnose a condition, confirm eligibility or replace formal screening by the study team.

Explore Wilson’s disease clinical trials through trialport

3. Consider whether participation fits your life

A study can be a good match on paper and still be difficult in practice. Worth thinking through:

the time each visit takes, and how many there are
travel, distance and who would come along
work, school or university commitments
caring responsibilities at home
support from family and friends
how you feel about blood tests, urine collections or a biopsy
how changing a treatment that currently works would feel
whether you understand the study well enough to decide, and whether it feels right

trialport’s readifit helps people reflect on their understanding, motivation, time, routines, support, emotions and practical arrangements.

4. Ask questions before deciding

Useful questions to put to a research team:

Why is this study being carried out, and what is already known?
Would I continue my current medicine, change it, or stop it?
What exactly would I need to do, and for how long?
What are the known risks, and what is still unknown?
Could I receive a placebo? A placebo is a dummy treatment with no active medicine, used so researchers can compare results fairly.
Can I leave the study after joining, and what happens to my usual treatment if I do?
Who provides my routine care, and who do I contact if I feel unwell?
Are travel and other costs covered?
What happens after the study ends, and will I be told the results?

Taking part is voluntary. A person can ask questions, speak with people they trust and choose not to participate.

Search for clinical trials at app.trialport.com.

Current research

Research falls into a few areas:

New copper-lowering medicines. ALXN1840, also called tiomolibdate choline, is an investigational once-daily tablet that binds copper in a different way. Its sponsor reported that a Phase 3 trial met its main goal and began a rolling submission to the United States Food and Drug Administration in July 2026. It is not approved [7].
Gene therapy. UX701 is an investigational one-off infusion designed to deliver a working copy of the ATP7B instructions to liver cells. Its sponsor reported in October 2024 that, in the first stage of a study in 15 adults, six people had stopped their usual copper-lowering treatment and a seventh had begun to reduce it, and that a further group would be enrolled at a higher dose. It is not approved [8].
Faster diagnosis, especially where the first symptoms are psychiatric [6].

Study status checked: 3 August 2026. Research moves and what is being studied changes, so this list will date. For current information, search at app.trialport.com.

Support and further information

In the United States, the Wilson Disease Association offers information for families, a list of centers of excellence, a patient registry and support group meetings [9]. In the United Kingdom, the Wilson’s Disease Support Group UK is a member-run charity with information on medication and diet, a patient register and a list of specialist clinics [10].

Elsewhere the position is uneven. Orphanet lists patient organizations and expert centers across Europe and beyond [4], and the NIDDK pages are clear and free to read [3]. Coverage in parts of Asia, Africa, the Middle East and South America is thin, and a national rare disease organization or a specialist liver unit is often the next contact.

Questions people often ask

Is Wilson’s disease curable?
No. Treatment lowers copper and keeps it down, and it continues for life. A liver transplant corrects the underlying liver problem and is used when the liver fails or medicines do not work [1,4].

What happens if it is not treated?
It gets progressively worse and is eventually fatal, which is why early diagnosis and steady treatment make such a difference [4].

Can someone with Wilson’s disease live a normal life span?
With treatment started early and taken consistently, the long-term outlook is very good [4]. Damage done to the brain before treatment starts may not fully reverse [1].

Will my children get it?
Only if they inherit a changed copy of the gene from both parents. Genetic counseling can work through the numbers for a family [1,4].

Should my brothers and sisters be tested?
Yes. Screening of first-degree relatives is recommended, since relatives who feel completely well can be found and treated before any damage occurs [1,4].

Sources

Weiss KH, Schilsky M. Wilson Disease. GeneReviews®. Seattle: University of Washington; initial posting 22 October 1999, last update 12 January 2023. https://www.ncbi.nlm.nih.gov/books/NBK1512/ Accessed 3 August 2026.
MedlinePlus Genetics, National Library of Medicine. Wilson disease. Last updated 11 July 2022. https://medlineplus.gov/genetics/condition/wilson-disease/ Accessed 3 August 2026.
National Institute of Diabetes and Digestive and Kidney Diseases. Definition & Facts for Wilson Disease. Last reviewed October 2018. https://www.niddk.nih.gov/health-information/liver-disease/wilson-disease/definition-facts Accessed 3 August 2026.
Orphanet. Wilson disease. ORPHA:905. Last update April 2021. https://www.orpha.net/en/disease/detail/905 Accessed 3 August 2026.
Wallace DF, Dooley JS. ATP7B variant penetrance explains differences between genetic and clinical prevalence estimates for Wilson disease. Human Genetics. 2020;139:1065-1075. https://link.springer.com/article/10.1007/s00439-020-02161-3 (DOI 10.1007/s00439-020-02161-3). Accessed 3 August 2026.
Antos A, Członkowska A, et al. Clinical Determinants and Prognostic Impact of Delayed Diagnosis in Wilson’s Disease. Diagnostics. 2025;15(18):2358. https://www.mdpi.com/2075-4418/15/18/2358 (DOI 10.3390/diagnostics15182358). Accessed 3 August 2026.
Monopar Therapeutics Inc. Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease. Press release, 22 July 2026. https://www.globenewswire.com/news-release/2026/07/22/3331283/0/en/Monopar-Initiates-Rolling-NDA-Submission-for-ALXN1840-in-Wilson-Disease.html Accessed 3 August 2026.
Ultragenyx Pharmaceutical Inc. Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease. Press release, 3 October 2024. https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-provides-update-stage-1-cohorts-pivotal-phase-123 Accessed 3 August 2026.
Wilson Disease Association. https://wilsondisease.org Accessed 3 August 2026.
Wilson’s Disease Support Group UK. https://wilsonsdisease.org.uk Accessed 3 August 2026.

Review information

Written by: trialport editorial team
Reviewed by: Keith Berelowitz, Founder and CEO, trialport
Reviewed on: 3 August 2026
Next review due: 3 August 2027
References last checked: 3 August 2026

Wilson’s disease: a plain-language guide